Top

Supportive Care in Cancer

Published in:

Open Access 01-01-2009 | Short Communication

Acute lymphoblastic leukemia and obesity: increased energy intake or decreased physical activity?

Authors: H. Jansen, A. Postma, R. P. Stolk, W. A. Kamps

Published in: Supportive Care in Cancer | Issue 1/2009

Abstract

Background

Obesity is a well-known problem in children with acute lymphoblastic leukemia (ALL), and it might be the result of an excess in energy intake, reduced energy expenditure, or both. The aim of this study is to describe energy intake and physical activity during treatment for ALL with intermittent dexamethasone (DEXA).

Methods

Body mass index (BMI), energy intake, and physical activity were measured in 16 ALL patients on maintenance treatment and in 17 healthy controls. ALL patients were measured during (“on DEXA”) and in between (“off DEXA”) DEXA treatments.

Results

In patients, the mean increase in BMI z-score was 1.4 ± 1.1. Energy intake on DEXA was higher (2,125.9 ± 476.0 vs 1,775.1 ± 426.1 kcal/24 h, p < 0.05) and energy intake off DEXA was lower (1,305.0 ± 249.4 vs 1,775.1 ± 426.1 kcal/24 h, p < 0.05), compared to healthy controls. Physical activity on DEXA was lower compared to healthy controls (30.0 ± 3.9 vs 40.0 ± 6.0 kcal kg⁻¹ 24 h⁻¹, p < 0.001 and 7,303.1 ± 4,622.9 vs 13,927.2 ± 3,822.7 steps, p < 0.05). Physical activity off DEXA was not different compared to healthy controls.

Conclusion

Weight gain in patients on ALL treatment might be owing to increased energy intake and decreased physical activity during treatment with DEXA.

Ainsworth BE, Haskell WL, Whitt MC, Irwin ML, Swartz AM, Strath SJ, O’Brien WL, Bassett DR Jr, Schmitz KH, Emplaincourt PO, Jacobs DR Jr, Leon AS (2000) Compendium of physical activities: an update of activity codes and MET intensities. Med Sci Sports Exerc 32(Suppl 9):S498–S504 doi:10.1097/00005768-200009001-00009 PubMed

Aznar S, Webster AL, San Juan AF, Chamorro-Vina C, Mate-Munoz JL, Moral S, Perez M, Garcia-Castro J, Ramirez M, Madero L, Lucia A (2006) Physical activity during treatment in children with leukemia: a pilot study. Appl Physiol Nutr Metab 31(4):407–413 doi:10.1139/H06-014 PubMedCrossRef

Beets MW, Patton MM, Edwards S (2005) The accuracy of pedometer steps and time during walking in children. Med Sci Sports Exerc 37(3):513–520 doi:10.1249/01.MSS.0000155395.49960.31 PubMedCrossRef

Bond SA, Han AM, Wootton SA, Kohler JA (1992) Energy intake and basal metabolic rate during maintenance chemotherapy. Arch Dis Child 67(2):229–232PubMed

Davies JH, Evans BA, Jones E, Evans WD, Jenney ME, Gregory JW (2004) Osteopenia, excess adiposity and hyperleptinaemia during 2 years of treatment for childhood acute lymphoblastic leukaemia without cranial irradiation. Clin Endocrinol (Oxf) 60(3):358–365 doi:10.1111/j.1365-2265.2003.01986.x CrossRef

Fredriks AM, van BS, Wit JM, Verloove-Vanhorick SP (2000) Body index measurements in 1996–7 compared with 1980. Arch Dis Child 82(2):107–112 doi:10.1136/adc.82.2.107 PubMedCrossRef

Jarfelt M, Lannering B, Bosaeus I, Johannsson G, Bjarnason R (2005) Body composition in young adult survivors of childhood acute lymphoblastic leukaemia. Eur J Endocrinol 153(1):81–89 doi:10.1530/eje.1.01931 PubMedCrossRef

Mayer EI, Reuter M, Dopfer RE, Ranke MB (2000) Energy expenditure, energy intake and prevalence of obesity after therapy for acute lymphoblastic leukemia during childhood. Horm Res 53(4):193–199 doi:10.1159/000023566 PubMedCrossRef

Reilly JJ, Brougham M, Montgomery C, Richardson F, Kelly A, Gibson BE (2001) Effect of glucocorticoid therapy on energy intake in children treated for acute lymphoblastic leukemia. J Clin Endocrinol Metab 86(8):3742–3745 doi:10.1210/jc.86.8.3742 PubMedCrossRef

10.

Reilly JJ, Ventham JC, Ralston JM, Donaldson M, Gibson B (1998) Reduced energy expenditure in preobese children treated for acute lymphoblastic leukemia. Pediatr Res 44(4):557–562 doi:10.1203/00006450-199810000-00015 PubMedCrossRef

11.

Sainsbury CP, Newcombe RG, Hughes IA (1985) Weight gain and height velocity during prolonged first remission from acute lymphoblastic leukaemia. Arch Dis Child 60(9):832–836PubMedCrossRef

12.

Van Dongen-Melman JE, Hokken-Koelega AC, Hahlen K, De GA, Tromp CG, Egeler RM (1995) Obesity after successful treatment of acute lymphoblastic leukemia in childhood. Pediatr Res 38(1):86–90 doi:10.1203/00006450-199507000-00015 PubMed

13.

Warner JT, Bell W, Webb DK, Gregory JW (1998) Daily energy expenditure and physical activity in survivors of childhood malignancy. Pediatr Res 43(5):607–613 doi:10.1203/00006450-199805000-00008 PubMedCrossRef

Title: Acute lymphoblastic leukemia and obesity: increased energy intake or decreased physical activity?
Authors: H. Jansen
A. Postma
R. P. Stolk
W. A. Kamps
Publication date: 01-01-2009
Publisher: Springer-Verlag
Published in: Supportive Care in Cancer / Issue 1/2009
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-008-0531-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2009

The prevalence of nutrition impact symptoms and their relationship to quality of life and clinical outcomes in medical oncology patients

Causal attributions to epidemiological risk factors and their associations to later psychological adjustment among Japanese breast cancer patients

The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial

Editorial—“Transition, change, growth, and sustainability”

Forecasting changes in preference over the life span: a qualitative study of African–American men’s prostate cancer decision making

Complementary and alternative medicine in patients with chronic lymphocytic leukemia

Keynote webinar | Spotlight on antibody–drug conjugates in cancer